Metagenomi Therapeutics (MGX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.78, -7.22% vs the prior close of $0.85.
- Volume 163.66K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MGX slides 7.2% to $0.78, a 52-week low, 4 down days in a row. Closed at $0.78, -7.22% vs the prior close of $0.85. Day range $0.77–$0.86, opened at $0.84.
MGX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — MGX slides 7.2% to $0.78, a 52-week low, 4 down days in a row
- Closed at $0.78, -7.22% vs the prior close of $0.85. Day range $0.77–$0.86, opened at $0.84.
- Volume was 163.66K shares, 1.0x its 50-day average of 161.85K.
- Price is -30.4% vs its 50-day average ($1.13) and -41.5% vs its 200-day average ($1.34).
- 52-week range $0.77–$3.95; today's close sits at 0% of that range, 80.2% below the 52-week high.
- That makes 4 straight losses.
Oct 15, 2026 — MGX dips 1.9% to $0.85, a 52-week low on 1.8x normal volume
- Closed at $0.85, -1.86% vs the prior close of $0.86. Day range $0.83–$0.88, opened at $0.86.
- Volume was 291.40K shares, 1.8x its 50-day average of 157.57K — unusually heavy trading.
- Price is -25.6% vs its 50-day average ($1.14) and -37.1% vs its 200-day average ($1.34).
- 52-week range $0.83–$3.95; today's close sits at 0% of that range, 78.6% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — MGX slides 6.1% to $0.86, a 52-week low on 1.9x normal volume
- Closed at $0.86, -6.11% vs the prior close of $0.92. Day range $0.86–$0.95, opened at $0.89.
- Volume was 293.50K shares, 1.9x its 50-day average of 153.92K — unusually heavy trading.
- Price is -24.7% vs its 50-day average ($1.14) and -36.1% vs its 200-day average ($1.35).
- 52-week range $0.86–$3.95; today's close sits at 0% of that range, 78.2% below the 52-week high.
Oct 13, 2026 — MGX slides 10.1% to $0.92, a 52-week low
- Closed at $0.92, -10.10% vs the prior close of $1.02. Day range $0.91–$1.03, opened at $1.02.
- Volume was 263.70K shares, 1.7x its 50-day average of 151.32K.
- Price is -20.2% vs its 50-day average ($1.15) and -32.2% vs its 200-day average ($1.35).
- 52-week range $0.91–$3.95; today's close sits at 0% of that range, 76.8% below the 52-week high.
Oct 12, 2026 — MGX rises 2.0% to $1.02, 3 up days in a row
- Closed at $1.02, +2.00% vs the prior close of $1.00. Day range $0.99–$1.06, opened at $1.00.
- Volume was 148.40K shares, 1.0x its 50-day average of 151.07K.
- Price is -11.7% vs its 50-day average ($1.16) and -24.8% vs its 200-day average ($1.36).
- 52-week range $0.96–$3.95; today's close sits at 2% of that range, 74.2% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — MGX rises 0.7% to $1.00
- Closed at $1.00, +0.70% vs the prior close of $0.99. Day range $0.99–$1.04, opened at $0.99.
- Volume was 147.10K shares, 1.0x its 50-day average of 150.78K.
- Price is -13.7% vs its 50-day average ($1.16) and -26.4% vs its 200-day average ($1.36).
- 52-week range $0.96–$3.95; today's close sits at 1% of that range, 74.7% below the 52-week high.
Oct 8, 2026 — MGX rises 0.8% to $0.99 on 2.5x normal volume
- Closed at $0.99, +0.81% vs the prior close of $0.99. Day range $0.96–$1.01, opened at $1.00.
- Volume was 354.50K shares, 2.5x its 50-day average of 144.40K — unusually heavy trading.
- Price is -14.6% vs its 50-day average ($1.16) and -27.1% vs its 200-day average ($1.36).
- 52-week range $0.96–$3.95; today's close sits at 1% of that range, 74.9% below the 52-week high.
Oct 7, 2026 — MGX slides 4.4% to $0.99, a 52-week low on 1.9x normal volume
- Closed at $0.99, -4.37% vs the prior close of $1.03. Day range $0.96–$1.02, opened at $1.01.
- Volume was 270.30K shares, 1.9x its 50-day average of 141.18K — unusually heavy trading.
- Price is -15.6% vs its 50-day average ($1.17) and -27.9% vs its 200-day average ($1.37).
- 52-week range $0.96–$3.95; today's close sits at 1% of that range, 75.1% below the 52-week high.
Oct 6, 2026 — MGX dips 1.0% to $1.03
- Closed at $1.03, -0.96% vs the prior close of $1.04. Day range $1.02–$1.08, opened at $1.07.
- Volume was 121.00K shares, 0.9x its 50-day average of 140.12K.
- Price is -12.1% vs its 50-day average ($1.17) and -24.8% vs its 200-day average ($1.37).
- 52-week range $1.01–$3.95; today's close sits at 1% of that range, 73.9% below the 52-week high.
Oct 5, 2026 — MGX rises 2.0% to $1.04
- Closed at $1.04, +1.96% vs the prior close of $1.02. Day range $1.01–$1.06, opened at $1.01.
- Volume was 163.20K shares, 1.2x its 50-day average of 138.18K.
- Price is -11.5% vs its 50-day average ($1.18) and -24.3% vs its 200-day average ($1.37).
- 52-week range $1.01–$3.95; today's close sits at 1% of that range, 73.7% below the 52-week high.
Oct 2, 2026 — MGX slides 7.7% to $1.02, a 52-week low
- Closed at $1.02, -7.69% vs the prior close of $1.11. Day range $1.01–$1.10, opened at $1.09.
- Volume was 121.80K shares, 0.9x its 50-day average of 136.79K.
- Price is -13.5% vs its 50-day average ($1.18) and -25.9% vs its 200-day average ($1.38).
- 52-week range $1.01–$3.95; today's close sits at 0% of that range, 74.2% below the 52-week high.
MGX latest news & SEC filings
Every SEC filing by or about MGX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Reid Laurence bought 19,883 shares at $1.17 (≈$23.26K) on Sep 9, 2026
- Reid Laurence bought 117 shares at $1.18 (≈$138) on Sep 9, 2026
- Reid Laurence bought 19,883 shares at $1.17 (≈$23.26K) on Sep 9, 2026
- Reid Laurence bought 117 shares at $1.18 (≈$138) on Sep 9, 2026
- Reid Laurence bought 19,883 shares at $1.17 (≈$23.26K) on Sep 9, 2026
- Reid Laurence bought 117 shares at $1.18 (≈$138) on Sep 9, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 10, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wein Matthew sold 358 shares at $1.16 (≈$415) on Sep 8, 2026
- Wein Matthew sold 358 shares at $1.16 (≈$415) on Sep 8, 2026
- Wein Matthew sold 358 shares at $1.16 (≈$415) on Sep 8, 2026
- Wein Matthew sold 358 shares at $1.16 (≈$415) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Irish Jian sold 2,140 shares at $1.16 (≈$2.48K) on Sep 8, 2026
- Irish Jian sold 2,140 shares at $1.16 (≈$2.48K) on Sep 8, 2026
- Irish Jian sold 2,140 shares at $1.16 (≈$2.48K) on Sep 8, 2026
- Irish Jian sold 2,140 shares at $1.16 (≈$2.48K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wapnick Pamela sold 1,911 shares at $1.16 (≈$2.22K) on Sep 8, 2026
- Wapnick Pamela sold 1,911 shares at $1.16 (≈$2.22K) on Sep 8, 2026
- Wapnick Pamela sold 1,911 shares at $1.16 (≈$2.22K) on Sep 8, 2026
- Wapnick Pamela sold 1,911 shares at $1.16 (≈$2.22K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$27.48M (prior year -$19.91M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.73 (prior year -$0.54) (loss widened vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade MGX
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 5, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.11% (largest 10.1%). That is a volatile stock.
- Liquidity: about 172.32K shares (≈$135.10K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.78 vs a range of $0.77–$3.95 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 17 sales; latest: Laurence Reid bought 19,883 shares on Sep 9, 2026.
- Latest filings: 8-K Sep 22, 2026; 10-Q Aug 10, 2026; 8-K Aug 10, 2026.
- Share count: 37.78M shares outstanding (Aug 6, 2026), +0.7% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
MGX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.84 | 0.86 | 0.77 | 0.78 | 163.66K |
| Oct 15, 2026 | 0.86 | 0.88 | 0.83 | 0.85 | 291.40K |
| Oct 14, 2026 | 0.89 | 0.95 | 0.86 | 0.86 | 293.50K |
| Oct 13, 2026 | 1.02 | 1.03 | 0.91 | 0.92 | 263.70K |
| Oct 12, 2026 | 1.00 | 1.06 | 0.99 | 1.02 | 148.40K |
| Oct 9, 2026 | 0.99 | 1.04 | 0.99 | 1.00 | 147.10K |
| Oct 8, 2026 | 1.00 | 1.01 | 0.96 | 0.99 | 354.50K |
| Oct 7, 2026 | 1.01 | 1.02 | 0.96 | 0.99 | 270.30K |
| Oct 6, 2026 | 1.07 | 1.08 | 1.02 | 1.03 | 121.00K |
| Oct 5, 2026 | 1.01 | 1.06 | 1.01 | 1.04 | 163.20K |
| Oct 2, 2026 | 1.09 | 1.10 | 1.01 | 1.02 | 121.80K |
| Oct 1, 2026 | 1.06 | 1.11 | 1.06 | 1.11 | 118.00K |
| Sep 30, 2026 | 1.13 | 1.13 | 1.06 | 1.06 | 152.00K |
| Sep 29, 2026 | 1.13 | 1.15 | 1.10 | 1.13 | 56.70K |
| Sep 28, 2026 | 1.13 | 1.16 | 1.13 | 1.14 | 132.00K |
| Sep 25, 2026 | 1.14 | 1.16 | 1.14 | 1.15 | 70.80K |
| Sep 24, 2026 | 1.12 | 1.16 | 1.12 | 1.15 | 211.50K |
| Sep 23, 2026 | 1.14 | 1.14 | 1.12 | 1.13 | 100.20K |
| Sep 22, 2026 | 1.07 | 1.16 | 1.07 | 1.14 | 165.10K |
| Sep 21, 2026 | 1.11 | 1.14 | 1.09 | 1.12 | 101.50K |
About Metagenomi Therapeutics
Metagenomi Therapeutics (MGX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in EMERYVILLE, CA. Fiscal year ends December 31. SEC CIK 1785279.
MGX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Eric Bjerkholt | Director | Jun 11, 2026 |
| Willard H Dere | Director | Jun 11, 2026 |
| Juergen Eckhardt | Director | Jun 11, 2026 |
| Jian Irish | See Remarks | Sep 10, 2026 |
| Laurence Reid | Director | Sep 11, 2026 |
| Brian C. Thomas | Director | Dec 8, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jian Irish | See Remarks | Sep 10, 2026 |
| Pamela Wapnick | Chief Financial Officer | Sep 10, 2026 |
| Matthew Wein | See Remarks | Sep 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 9, 2026 | Laurence Reid | Buy | 19,883 | $1.17 |
| Sep 9, 2026 | Laurence Reid | Buy | 117 | $1.18 |
| Sep 9, 2026 | Laurence Reid | Buy | 19,883 | $1.17 |
| Sep 9, 2026 | Laurence Reid | Buy | 117 | $1.18 |
| Sep 9, 2026 | Laurence Reid | Buy | 19,883 | $1.17 |
| Sep 9, 2026 | Laurence Reid | Buy | 117 | $1.18 |
| Sep 9, 2026 | Laurence Reid | Buy | 19,883 | $1.17 |
| Sep 9, 2026 | Laurence Reid | Buy | 117 | $1.18 |
| Sep 8, 2026 | Jian Irish | Sale | 2,140 | $1.16 |
| Sep 8, 2026 | Jian Irish | Sale | 2,140 | $1.16 |
| Sep 8, 2026 | Jian Irish | Sale | 2,140 | $1.16 |
| Sep 8, 2026 | Jian Irish | Sale | 2,140 | $1.16 |
| Sep 8, 2026 | Matthew Wein | Sale | 358 | $1.16 |
| Sep 8, 2026 | Matthew Wein | Sale | 358 | $1.16 |
| Sep 8, 2026 | Matthew Wein | Sale | 358 | $1.16 |
MGX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $25.21M | $-87.87M | -2.36 | $-88.89M |
| Dec 31, 2024 | $52.30M | $-78.06M | -2.36 | $-109.07M |
| Dec 31, 2023 | $44.76M | $-68.25M | -20.05 | $-91.41M |
Latest balance sheet: total assets $173.70M, total liabilities $61.13M, cash $39.03M (as of Jun 30, 2026).
MGX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $1.23 |
| May 11, 2026 | 8-K Item 2.02 (results) | $1.35 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $1.61 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.86 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.88 |
| May 13, 2025 | 8-K Item 2.02 (results) | $1.60 |
| Mar 17, 2025 | 8-K Item 2.02 (results) | $1.88 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $2.11 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
| Mar 27, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on MGX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.